Brief: Roche Spokesperson Says Decided To Stop Clinical Development Of Emugrobart For Spinal Muscular Atrophy & Facioscapulohumeral Muscular Dystrophy
20/03/2026 16:05
March 20 (Reuters) - Roche Holding AG ROPC.S: ROCHE SPOKESPERSON: DECIDED TO STOP CLINICAL DEVELOPMENT OF EMUGROBART FOR BOTH SPINAL MUSCULAR ATROPHY & FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY ROCHE SPOKESPERSON: PHASE II DEVELOPMENT OF EMUGROBART IN OBESITY CONTINUES AS PLANNED Source text: [ID:] Further company coverage: ROPC.S ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Roche Holding AG
See all newsTable: Swiss trade surplus at CHF 6.11 bln in May
Brief: Roche - FDA Accepts Supplemental Biologics License Application For Lunsumio And Polivy Combination
Swiss stocks - Factors to watch on June 18
FDA approves first generic version of Roche's flu drug
Brief: FDA Approves First Single-Dose Generic Treatment For Influenza